Ladiratuzumab vedotin (anti-SLC39A6) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin (anti-SLC39A6) has the potential for use in multiple carcinomas. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
规格
产品名称
Ladiratuzumab vedotin (anti-SLC39A6), 微管蛋白抑制剂
别名
纬拉妥珠单抗 | 拉迪鲁珠单抗维多汀(抗 SLC39A6)
英文别名
Estrogen regulated protein LIV 1 6 antibody | Estrogen-regulated protein LIV-1 antibody | LIV 1 antibody | LIV 1 protein, estrogen regulated antibody | S39A6_HUMAN antibody | SLC39A6 antibody | Solute carrier family 39 (metal ion transporter), member 6 an
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry Flow Cytometry analysis of Jurkat cells labelling SLC39A6 (red) with Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry Flow Cytometry analysis of ZDFH001-human-LIV1 A6-C2203027 cells at 1×105 cell/well can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 80.0 ng/mL.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - SEC The purity of Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) is more than 95% verified by HPLC.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - ELISA Immobilized Recombinant Human SLC39A6/LIV-1 Protein (rp176717) at 1.0 μg/mL can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 18.4 ng/mL.